Based in Paris, France, Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing nanoparticle-based oncology treatments. The company's lead product candidate is NBTXR3, a suspension of crystalline hafnium oxide nanoparticles designed to enhance the effectiveness of radiation therapy across multiple cancer types, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
The company operates primarily through product development activities. Nanobiotix has established a strategic partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand, enabling geographic diversification of commercialization efforts. As of the most recent reporting period, the company maintains a small operational footprint with 103 full-time employees, consistent with a clinical-stage organization focused on drug development rather than commercial-scale operations.
Nanobiotix was founded in 2003 and trades on the Nasdaq exchange, with a current market capitalization of approximately $1.3 billion. The company's geographic reach extends primarily through its French headquarters and its partnership arrangements in Asia-Pacific markets.
No 10-K filings found.